Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
Beam Therapeutics reported Q3 2024 financial results and program updates. The company has enrolled 35 patients and dosed eight in the BEACON Phase 1/2 trial of BEAM-101 for sickle cell disease. Initial clinical data will be presented at the upcoming ASH Annual Meeting. The first cohort dosing is completed for BEAM-302 in Alpha-1 Antitrypsin Deficiency, with data expected in 2025.
Financial highlights include $925.8M in cash and equivalents, with runway into 2027. Q3 net loss was $96.7M ($1.17 per share), with R&D expenses at $94.3M and G&A expenses at $26.5M. The company nominated development candidates BEAM-103 and BEAM-104 for its ESCAPE technology.
Beam Therapeutics ha riportato i risultati finanziari e gli aggiornamenti sui programmi del terzo trimestre 2024. La società ha arruolato 35 pazienti e ha somministrato il trattamento a otto di essi nel trial di fase 1/2 BEACON per la malattia delle cellule falciformi. I dati clinici iniziali saranno presentati al prossimo incontro annuale ASH. La somministrazione del primo gruppo è stata completata per BEAM-302 nella Deficienza di Alpha-1 Antitripsina, con i dati attesi per il 2025.
I punti salienti finanziari includono 925,8 milioni di dollari in contante e equivalenti, con runway fino al 2027. La perdita netta del terzo trimestre è stata di 96,7 milioni di dollari (1,17 dollari per azione), con spese per R&D di 94,3 milioni di dollari e spese generali e amministrative di 26,5 milioni di dollari. La società ha nominato i candidati allo sviluppo BEAM-103 e BEAM-104 per la sua tecnologia ESCAPE.
Beam Therapeutics reportó los resultados financieros del tercer trimestre de 2024 y actualizaciones de programas. La compañía ha inscrito a 35 pacientes y ha administrado dosis a ocho en el ensayo de fase 1/2 BEACON para la enfermedad de células falciformes. Los datos clínicos iniciales se presentarán en la próxima reunión anual de ASH. La dosificación del primer grupo se ha completado para BEAM-302 en la Deficiencia de Alfa-1 Antitripsina, con datos esperados para 2025.
Los aspectos destacados financieros incluyen 925,8 millones de dólares en efectivo y equivalentes, con una duración financiera hasta 2027. La pérdida neta del tercer trimestre fue de 96,7 millones de dólares (1,17 dólares por acción), con gastos de I+D de 94,3 millones de dólares y gastos generales y administrativos de 26,5 millones de dólares. La compañía ha nominado a los candidatos de desarrollo BEAM-103 y BEAM-104 para su tecnología ESCAPE.
Beam Therapeutics는 2024년 3분기 재무 결과 및 프로그램 업데이트를 보고했습니다. 이 회사는 35명의 환자를 등록했고, 세포 sickle 질환을 위한 BEAM-101의 BEACON 1/2상 시험에서 8명에게 투약했습니다. 초기 임상 데이터는 다가오는 ASH 연례 회의에서 발표될 예정입니다. 알파-1 안티트립신 결핍증에 대한 BEAM-302의 첫 번째 그룹 투약이 완료되었으며, 데이터는 2025년에 예상됩니다.
재정 하이라이트에는 9억 2,580만 달러의 현금 및 현금 등가물이 포함되어 있으며, 이는 2027년까지의 자금 여력이 있습니다. 3분기 순손실은 9,670만 달러(주당 1.17달러)로, 연구 및 개발 비용은 9,430만 달러, 일반 관리 비용은 2,650만 달러였습니다. 이 회사는 ESCAPE 기술을 위한 개발 후보로 BEAM-103 및 BEAM-104를 제안했습니다.
Beam Therapeutics a rapporté les résultats financiers du troisième trimestre 2024 ainsi que des mises à jour sur les programmes. L'entreprise a recruté 35 patients et en a traité huit dans l'essai de phase 1/2 BEACON pour la maladie des cellules falciformes. Les premières données cliniques seront présentées lors de la prochaine réunion annuelle de l'ASH. L'administration du premier cohorte pour BEAM-302 dans le cadre de la Déficience en Alpha-1 Antitrypsine a été achevée, avec des données attendues en 2025.
Les points financiers saillants incluent 925,8 millions de dollars en liquidités et équivalents, avec une autonomie jusqu'en 2027. La perte nette du troisième trimestre était de 96,7 millions de dollars (1,17 dollar par action), avec des dépenses de R&D de 94,3 millions de dollars et des dépenses générales et administratives de 26,5 millions de dollars. L'entreprise a nommé les candidats au développement BEAM-103 et BEAM-104 pour sa technologie ESCAPE.
Beam Therapeutics hat die finanziellen Ergebnisse und Programmupdates für das dritte Quartal 2024 veröffentlicht. Das Unternehmen hat 35 Patienten rekrutiert und acht davon in der BEACON Phase 1/2 Studie mit BEAM-101 für die Sichelzellenkrankheit behandelt. Erste klinische Daten werden auf der bevorstehenden ASH-Jahrestagung präsentiert. Die Dosierung der ersten Kohorte für BEAM-302 bei Alpha-1-Antitrypsin-Mangel ist abgeschlossen, wobei die Daten für 2025 erwartet werden.
Die finanziellen Highlights umfassen 925,8 Millionen US-Dollar in bar und Äquivalenten, mit Spielraum bis 2027. Der Nettogewinn im dritten Quartal betrug 96,7 Millionen US-Dollar (1,17 US-Dollar pro Aktie), mit F&E-Ausgaben von 94,3 Millionen US-Dollar und allgemeinen Verwaltungskosten von 26,5 Millionen US-Dollar. Das Unternehmen hat die Entwicklungs Kandidaten BEAM-103 und BEAM-104 für seine ESCAPE-Technologie nominiert.
- Strong cash position of $925.8M providing runway into 2027
- 35 patients enrolled and 8 dosed in BEAM-101 trial showing clinical progress
- First cohort dosing completed for BEAM-302 trial
- Reduced R&D expenses to $94.3M from $100.0M year-over-year
- Net loss increased to $96.7M from $96.1M year-over-year
- Cash position decreased from $1.2B to $925.8M since December 2023
- G&A expenses increased to $26.5M from $25.4M year-over-year
Insights
Beam Therapeutics demonstrates solid financial stability with
The extended cash runway provides substantial operational flexibility for key clinical milestones across five programs. Notable progress in patient enrollment (35 patients in BEACON trial) and expansion of clinical sites globally strengthen the company's development pipeline. The upcoming ASH presentations and 2025 data readouts could serve as significant catalysts for market valuation.
The clinical progress across multiple programs shows promising momentum. The BEACON trial's enrollment of 35 patients with 8 already dosed represents significant advancement in the sickle cell disease program. The completion of first cohort dosing for BEAM-302 in AATD and the FDA clearance for BEAM-301's IND demonstrate efficient pipeline execution.
The development of ESCAPE technology with BEAM-103/104 represents an innovative approach to genetic medicine, potentially offering improved treatment options for both sickle cell disease and beta-thalassemia. The multiple presentations accepted at ASH, including initial clinical data and preclinical NHP results, suggest strong scientific validation of the base editing platform.
Initial Clinical Data for BEAM-101 and Preclinical Non-human Primate Data for ESCAPE Accepted for Presentation at American Society of Hematology (ASH) Annual Meeting
35 Patients Enrolled and Eight Patients Dosed in BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease
First Cohort Dosing Completed in Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency; Initial Clinical Data Expected in 2025
Ended Third Quarter 2024 with
Company to Host Conference Call Today, November 5, 2024, at 8:30 a.m. ET
CAMBRIDGE, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today reported third quarter 2024 financial results and provided updates across the company’s hematology and genetic disease franchises.
“In the third quarter, we demonstrated strong execution across our priority hematology and liver genetic disease programs, with progress in clinical site activation, patient enrollment and dosing,” said John Evans, chief executive officer of Beam. “The imminent presentation of our BEAM-101 clinical data in patients with sickle cell disease, along with preclinical data for ESCAPE, at the ASH Annual Meeting is an important milestone for Beam’s base editing technology. In our in vivo portfolio, the BEAM-302 clinical program in alpha-1 antitrypsin deficiency is expanding globally, with dosing complete for the first cohort of patients and data anticipated in 2025, while BEAM-301 has achieved an open IND with the FDA upon first review. We are now entering a catalyst-rich period for Beam, with a strong cash position supporting both the execution of our development programs and our long-term investment in a highly differentiated product engine.”
Third Quarter 2024 and Recent Progress
- Four Beam abstracts were accepted for presentation at the upcoming American Society of Hematology (ASH) Annual Meeting, including two abstracts on the initial clinical data from the BEACON trial of BEAM-101, one on the clinical data for BEAM-201, and one on the preclinical non-human primate (NHP) data for the Engineered Stem Cell Antibody Paired Evasion (ESCAPE) conditioning platform. Beam will host an investor webcast and conference call today at 8:30 a.m. ET to review the abstracts. Abstracts will be available on the ASH website today at 9 a.m. ET.
- To date, 35 patients have cleared screening and enrolled in the BEACON Phase 1/2 clinical trial of BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). Of these patients, eight have been dosed with BEAM-101, with the other enrolled patients going through pre-transplant stages, including cell collection and drug product manufacturing.
- Patient enrollment in the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency (AATD) is progressing, with continued site activation globally and dosing completed for the first cohort.
- Beam has nominated a development candidate for its ESCAPE technology comprised of two investigational drug products: BEAM-103, an anti-CD117 monoclonal antibody (mAb), and BEAM-104, a cell therapy that includes the same therapeutic edit as BEAM-101 (editing the HBG1/2 genes to elevate fetal hemoglobin), plus an additional edit to CD117 which is designed to prevent binding of BEAM-103, allowing the edited cells to evade suppression by the antibody. The company intends to advance BEAM-103 and BEAM-104 for development in SCD and beta-thalassemia, potentially building on the same regulatory, manufacturing, clinical and commercial foundations being established for BEAM-101.
Key Anticipated Milestones
Hematology Franchise
- In conjunction with the ASH Annual Meeting taking place December 7-10, 2024, Beam will present additional data from the BEACON Phase 1/2 clinical trial of BEAM-101 and additional preclinical NHP data for ESCAPE. The company will host an investor event to review the data on Sunday, December 8, at 8 p.m. PT.
- The company anticipates initiating Phase 1-enabling preclinical studies for ESCAPE by the end of 2024.
Genetic Disease Franchise
- Beam expects to report initial clinical data from multiple cohorts in the Phase 1/2 clinical trial of BEAM-302 in patients with AATD in 2025.
- The company is continuing site activation activities for the Phase 1/2 clinical trial for BEAM-301 in glycogen storage disease type 1a (GSDIa), with patient dosing expected to commence in early 2025.
Oncology
- Data from the Phase 1/2 clinical trial of BEAM-201, a multiplex-edited allogeneic CAR-T product candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL)/T-cell lymphoblastic lymphoma (T-LL), will be presented at the ASH Annual Meeting.
Third Quarter 2024 Financial Results
- Cash Position: Cash, cash equivalents and marketable securities were
$925.8 million as of September 30, 2024, compared to$1.2 billion as of December 31, 2023. - Research & Development (R&D) Expenses: R&D expenses were
$94.3 million for the third quarter of 2024, compared to$100.0 million for the third quarter of 2023. - General & Administrative (G&A) Expenses: G&A expenses were
$26.5 million for the third quarter of 2024, compared to$25.4 million for the third quarter of 2023. - Net Loss: Net loss was
$96.7 million for the third quarter of 2024, or$1.17 per share, compared to$96.1 million for the third quarter of 2023, or$1.22 per share.
Cash Runway
Beam expects that its cash, cash equivalents and marketable securities as of September 30, 2024, will enable the company to fund its anticipated operating expenses and capital expenditure requirements into 2027. This expectation includes funding directed toward reaching each of the key anticipated milestones for BEAM-101, BEAM-103, BEAM-104, BEAM-301 and BEAM-302 described above, as well as continued investments in platform advancements and manufacturing capabilities, and excludes commercial spend related to the potential launch of BEAM-101.
Conference Call and Webcast Details
Beam will host a conference call and webcast to discuss these updates today, November 5, 2024, at 8:30 a.m. ET. A live webcast of the presentation will be available here and under "Events & Presentations" in the Investors section of the company's website at www.beamtx.com. A replay of the webcast will be archived on the company’s website for 60 days following the presentation.
About Beam Therapeutics
Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform with integrated gene editing, delivery and internal manufacturing capabilities. Beam’s suite of gene editing technologies is anchored by base editing, a proprietary technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This has the potential to enable a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the therapeutic applications and potential of our technology, including with respect to SCD, T-ALL/T-LL, AATD, GSDIa, and ESCAPE; our plans, and anticipated timing, to advance our programs; the clinical trial designs and expectations for BEAM-101, BEAM-201, BEAM-301, BEAM-302 and ESCAPE; our potential presentations at the ASH annual meeting; our estimated cash, cash equivalents and marketable securities as of September 30, 2024 and our expectations related thereto; the sufficiency of our capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available; and our ability to develop life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to important risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the uncertainty that our product candidates will receive regulatory approval necessary to initiate human clinical trials; that preclinical testing of our product candidates and preliminary or interim data from preclinical studies and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that initiation and enrollment of, and anticipated timing to advance, our clinical trials may take longer than expected; that our product candidates or the delivery modalities we rely on to administer them may cause serious adverse events; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the headings “Risk Factors Summary” and “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2023, our Quarterly Reports on Form 10-Q and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.
Contacts:
Investors:
Holly Manning
Beam Therapeutics
hmanning@beamtx.com
Media:
Dan Budwick
1AB
dan@1abmedia.com
| Condensed Consolidated Balance Sheet Data (unaudited) | ||||||||
| (in thousands) | ||||||||
| September 30, 2024 | December 31, 2023 | |||||||
| Cash, cash equivalents, and marketable securities | $ | 925,757 | $ | 1,189,876 | ||||
| Total assets | 1,171,367 | 1,459,714 | ||||||
| Total liabilities | 380,050 | 478,385 | ||||||
| Total stockholders’ equity | 791,317 | 981,329 | ||||||
| Condensed Consolidated Statement of Operations (unaudited) | ||||||||||||||||
| (in thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||||
| License and collaboration revenue | $ | 14,269 | $ | 17,193 | $ | 33,451 | $ | 61,517 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 94,258 | 100,050 | 266,117 | 297,304 | ||||||||||||
| General and administrative | 26,515 | 25,410 | 82,865 | 73,556 | ||||||||||||
| Total operating expenses | 120,773 | 125,460 | 348,982 | 370,860 | ||||||||||||
| Loss from operations | (106,504 | ) | (108,267 | ) | (315,531 | ) | (309,343 | ) | ||||||||
| Other income (expense): | ||||||||||||||||
| Change in fair value of derivative liabilities | (200 | ) | 4,700 | 2,400 | 9,400 | |||||||||||
| Change in fair value of non-controlling equity investments | (2,064 | ) | (11,221 | ) | (13,003 | ) | (17,870 | ) | ||||||||
| Change in fair value of contingent consideration liabilities | (27 | ) | 6,002 | 1,619 | 7,877 | |||||||||||
| Interest and other income (expense), net | 12,127 | 12,698 | 38,166 | 34,612 | ||||||||||||
| Total other income (expense) | 9,836 | 12,179 | 29,182 | 34,019 | ||||||||||||
| Net loss before income taxes | $ | (96,668 | ) | $ | (96,088 | ) | $ | (286,349 | ) | $ | (275,324 | ) | ||||
| Provision for income taxes | — | — | (39 | ) | — | |||||||||||
| Net loss | $ | (96,668 | ) | $ | (96,088 | ) | $ | (286,388 | ) | $ | (275,324 | ) | ||||
| Unrealized gain (loss) on marketable securities | 2,869 | (9 | ) | 1,155 | 406 | |||||||||||
| Comprehensive loss | $ | (93,799 | ) | $ | (96,097 | ) | $ | (285,233 | ) | $ | (274,918 | ) | ||||
| Net loss per common share, basic and diluted | $ | (1.17 | ) | $ | (1.22 | ) | $ | (3.49 | ) | $ | (3.63 | ) | ||||
| Weighted-average common shares outstanding, basic and diluted | 82,410,095 | 79,024,647 | 82,141,383 | 75,902,612 | ||||||||||||
FAQ
What were Beam Therapeutics (BEAM) Q3 2024 financial results?
How many patients are enrolled in BEAM-101's BEACON trial?
When will Beam Therapeutics (BEAM) present BEAM-302 clinical data?
How long will Beam Therapeutics' (BEAM) current cash runway last?
